1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Original Article
You have full text access to this OnlineOpen article
10-year follow-up after interferon-α therapy for chronic hepatitis C
Article first published online: 30 DEC 2003
DOI: 10.1002/hep.510280430
Copyright © 1998 by the American Association for the Study of Liver Diseases
1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
Additional Information
How to Cite
Lau, D. T., Kleiner, D. E., Ghany, M. G., Park, Y., Schmid, P. and Hoofnagle, J. H. (1998), 10-year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology, 28: 1121–1127. doi: 10.1002/hep.510280430
Publication History
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
- Manuscript Accepted: 1 JUN 1998
- Manuscript Received: 2 APR 1998
- Abstract
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , Effects of a Sustained Virologic Response on Outcomes of Patients With Chronic Hepatitis C, Clinical Gastroenterology and Hepatology, 2011,
- 2, , Evolution of Interferon-Based Therapy for Chronic Hepatitis C, Hepatitis Research and Treatment, 2010, 2010, 1
- 3, , , , , , , , How sustained is sustained viral response in patients with hepatitis C virus infection?, Indian Journal of Gastroenterology, 2010, 29, 3, 112
- 4, , Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C, Hepatitis Research and Treatment, 2010, 2010, 1
- 5, , , , , , , , Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C, Journal of Viral Hepatitis, 2010, 17, 1Direct Link:
- 6, , , , , , , , , , , , , , , Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C, Hepatology Research, 2010, 40, 4Direct Link:
- 7, , Telaprevir: a new hope in the treatment of chronic hepatitis C?, Advances in Therapy, 2010, 27, 8, 512
- 8, , , , , , , , , , , , , Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin, Hepatology, 2010, 51, 4Direct Link:
- 9, Benefits and risks of nucleoside analog therapy for hepatitis B, Hepatology, 2009, 49, S5Direct Link:
- 10, , , , , , Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients, Hepatology, 2009, 49, 3Direct Link:
- 11, , Occult hepatitis C: How convincing are the current data?, Hepatology, 2009, 49, 2Direct Link:
- 12, , Using high-throughput genomics to study hepatitis C: What determines the outcome of infection?, Antiviral Research, 2009, 81, 3, 198
- 13, Clinical management of HIV/hepatitis C virus coinfection, Journal of the American Academy of Nurse Practitioners, 2008, 20, 10Direct Link:
- 14, , , , , , , , , , , , , , Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C, Gastroenterology, 2008, 135, 3, 821
- 15, , , , , How Physicians Describe Outcomes to HCV Therapy, Journal of Clinical Gastroenterology, 2008, 42, 4, 419
- 16, , , , , Innate immune modulation by RNA viruses: emerging insights from functional genomics, Nature Reviews Immunology, 2008, 8, 8, 644
- 17, , , , , , , , , , , , , , Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction–negative samples obtained after treatment of chronic hepatitis C, Hepatology, 2008, 48, 5Direct Link:
- 18, , , , , , Pegylated Interferon Alpha-2b Plus Ribavirin for Naive Patients With HCV-related Cirrhosis, Journal of Clinical Gastroenterology, 2008, 42, 6, 734
- 19, , , , , , , Recurrence of HCV Infection in a Sustained Responder After Chemotherapy for Non-Hodgkinʼs Lymphoma: Successful Retreatment, The American Journal of the Medical Sciences, 2008, 336, 1, 73
- 20, , Treatment strategy for hepatitis C after liver transplantation, Journal of Hepato-Biliary-Pancreatic Surgery, 2008, 15, 2, 111
- 21, , , , , , , Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study, Journal of Thrombosis and Haemostasis, 2007, 5, 8Direct Link:
- 22, , Changing Treatment Paradigms: Hepatitis C Virus in HIV-Infected Patients, AIDS Patient Care and STDs, 2007, 21, 3, 154
- 23, , , , , , , Cost-effectiveness of Treatment for Hepatitis C in an Urban Cohort Co-infected with HIV, The American Journal of Medicine, 2007, 120, 3, 272
- 24, , Improving the treatment of hepatitis C infection in the UK, Expert Opinion on Pharmacotherapy, 2007, 8, 2, 183
- 25, , Interferon-based therapy of hepatitis C, Advanced Drug Delivery Reviews, 2007, 59, 12, 1222
- 26, , , Outcome of Screening for Hepatitis C Virus Infection Based on Risk Factors, The American Journal of Gastroenterology, 2007, 0, 0, 070925110728001
- 27, , Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C, Future Virology, 2007, 2, 6, 553
- 28, , , , , , Effect of anti-viral therapy for occult hepatitis C virus infection, Alimentary Pharmacology & Therapeutics, 2006, 23, 8Direct Link:
- 29, , , , , , , , , , , , , , HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial, Hepatology, 2006, 44, 2Direct Link:
- 30
- 31, , Improving anti-hepatitis C virus therapy, Expert Opinion on Biological Therapy, 2006, 6, 9, 923
- 32, , , , , , , , , Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis, Journal of Viral Hepatitis, 2006, 13, 6Direct Link:
- 33, , , , , , , Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy, Alimentary Pharmacology & Therapeutics, 2006, 23, 4Direct Link:
- 34, , , , , , , Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting, Journal of Viral Hepatitis, 2006, 13, 5Direct Link:
- 35, Therapy of hepatitis C: From empiricism to eradication, Hepatology, 2006, 43, S1Direct Link:
- 36, , , , , , Two cases of chronic hepatitis C with sustained virological response in whom serum HCV RNA reappeared two or twelve years after the end of IFN treatment, Kanzo, 2006, 47, 12, 550
- 37, , , , , , Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus, Journal of Gastroenterology and Hepatology, 2005, 20, 10Direct Link:
- 38, , Mechanism of action of interferon and ribavirin in treatment of hepatitis C, Nature, 2005, 436, 7053, 967
- 39, , , , , , , , , , Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C, Hepatology, 2005, 41, 1Direct Link:
- 40, Prepared minds and the introduction of imaginon for hepatitic contagions, Hepatology, 2005, 41, 6Direct Link:
- 41, , Routine hepatitis C virus screening in pregnancy: A cost-effectiveness analysis, American Journal of Obstetrics and Gynecology, 2005, 192, 4, 1153
- 42, , , , , , , , , , , Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany, The European Journal of Health Economics, 2005, 6, 2, 112
- 43, , , , , Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis, Clinical Gastroenterology and Hepatology, 2004, 2, 3, 183
- 44, , , , , , , , Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C, PharmacoEconomics, 2004, 22, 4, 257
- 45, Cost-effectiveness of pegylated IFN-α2band -2aand ribavirin for chronic hepatitis C treatment, Expert Review of Pharmacoeconomics & Outcomes Research, 2004, 4, 5, 495
- 46, Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C, Journal of Viral Hepatitis, 2004, 11, 3Direct Link:
- 47
- 48, , , , , In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-α and ribavirin combination, Antiviral Research, 2004, 61, 2, 111
- 49, , , , , , , , Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy, Journal of Medical Virology, 2004, 74, 3Direct Link:
- 50
- 51, , Peginterferon alfa-2a: A review of approved and investigational uses, Clinical Therapeutics, 2004, 26, 7, 991
- 52, , , , , , Regression of Liver Fibrosis in Cases of Chronic Liver Disease Type C: Quantitative Evaluation by Using Computed Image Analysis, Internal Medicine, 2004, 43, 10, 902
- 53, Regression of Liver Fibrosis in Patients Treated By Interferon, Internal Medicine, 2004, 43, 10, 887
- 54, , , , , , A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2003, 17, 5Direct Link:
- 55, , Antiviral therapy for hepatitis C, Current Treatment Options in Gastroenterology, 2003, 6, 6, 445
- 56, , , Comparison of 125I-interferon-α binding to peripheral blood cells from African–Americans and Caucasians with hepatitis C, Journal of Viral Hepatitis, 2003, 10, 5Direct Link:
- 57Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions, The American Journal of Gastroenterology, 2003, 98, 11, 2344
- 58, , , , First phase hepatitis c viral kinetics in previous nonresponders patients, Journal of Viral Hepatitis, 2003, 10, 1Direct Link:
- 59, , , , First, do not harm: power, oppression, and violence of liver biopsy, Gastroenterology, 2003, 125, 1, 272
- 60, , , , Hepatitis C and renal disease: an update 1 1Summary of a workshop held October 21 to 22, 2002, in the Lister Hill Auditorium, The National Institutes of Health, Bethesda, MD., American Journal of Kidney Diseases, 2003, 42, 4, 631
- 61, , , Hepatitis C–HIV coinfection: current and future therapy, Expert Review of Anti-infective Therapy, 2003, 1, 3, 433
- 62, , , , , , , , , , , Histological improvement of chronic liver disease after spontaneous serum hepatitis C virus clearance, Journal of Medical Virology, 2003, 69, 1Direct Link:
- 63, , , , Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses, Antiviral Research, 2003, 58, 1, 73
- 64, , , , , , Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon, Journal of Viral Hepatitis, 2003, 10, 2Direct Link:
- 65, , , Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C, Current Hepatitis Reports, 2003, 2, 1, 24
- 66, , Treatment of chronic hepatitis C in patients who have failed to respond to IFN or IFN and ribavirin combination therapy, Current Hepatitis Reports, 2003, 2, 1, 32
- 67, , , , , , , , , Triple Combination of Interferon Alpha-2b, Ribavirin, and Amantadine for Treatment of Chronic Hepatitis C, Journal of Clinical Gastroenterology, 2003, 36, 5, 427
- 68
- 69
- 70, , Advances in therapy for hepatitis C infection, Microbes and Infection, 2002, 4, 12, 1237
- 71, , Current and future hepatitis C virus diagnostic testing: problems and advancements, Microbes and Infection, 2002, 4, 12, 1227
- 72, Developments in the treatment of chronic hepatitis C, Expert Opinion on Investigational Drugs, 2002, 11, 4, 515
- 73, Efficacy of lamivudine in HBeAg-negative chronic hepatitis B, Journal of Medical Virology, 2002, 66, 4Direct Link:
- 74, Hepatitis C advances in antiviral therapy: What is accepted treatment now?, Journal of Gastroenterology and Hepatology, 2002, 17, 4Direct Link:
- 75, Introduction to therapy of hepatitis C, Hepatology, 2002, 36, S1Direct Link:
- 76, Management of viral hepatitis C, Journal of Gastroenterology and Hepatology, 2002, 17,Direct Link:
- 77
- 78, , , , Polyethylene glycol–interferon: Current status in hepatitis C virus therapy, Journal of Gastroenterology and Hepatology, 2002, 17,Direct Link:
- 79, , , The HCV and HIV coinfected patient: What have we learned about pathophysiology?, Current Gastroenterology Reports, 2002, 4, 1, 15
- 80, , , Treatment of chronic hepatitis C with PEGylated interferon and ribavirin, Current Gastroenterology Reports, 2002, 4, 1, 23
- 81, , , , , , , Treatment of chronic hepatitis C: A systematic review, Hepatology, 2002, 36, S1Direct Link:
- 82, Treatment of Hepatitis C and Anemia in Human Immunodeficiency Virus–Infected Patients, The Journal of Infectious Diseases, 2002, 185, s2, S128
- 83, , , , Which is the Most Cost-Effective Combination Therapy Strategy Using Interferon ??-2b plus Ribavirin for Na??ve Patients with Chronic Hepatitis C?, Clinical Drug Investigation, 2002, 22, 1, 31
- 84
- 85, , , , , , , , , Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels, Journal of Viral Hepatitis, 2001, 8, 5Direct Link:
- 86, , CURRENTTREATMENTSTRATEGIES FORCHRONICHEPATITISBANDC, Annual Review of Medicine, 2001, 52, 1, 29
- 87, , , , , , , , , , , Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation, The American Journal of Gastroenterology, 2001, 96, 4, 1170
- 88, , , Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-α therapy, Journal of Medical Virology, 2001, 65, 3Direct Link:
- 89, , , , , , , Long-term follow up of chronic hepatitis C patients after α-interferon treatment: A functional study, Journal of Gastroenterology and Hepatology, 2001, 16, 4Direct Link:
- 90, , , , , , , Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response, Alimentary Pharmacology & Therapeutics, 2001, 15, 2Direct Link:
- 91, Use of Corticosteroid Therapy in Autoimmune Hepatitis Resulting in the Resolution of Cirrhosis, Journal of Clinical Gastroenterology, 2001, 32, 5, 371
- 92, , , Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection, Journal of Viral Hepatitis, 2001, 8, 1, 1
- 93, , , Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection, Journal of Viral Hepatitis, 2001, 8, 1Direct Link:
- 94, , , Antiviral Therapy of HBV- and HCV-induced Liver Cirrhosis, Journal of Clinical Gastroenterology, 2000, 30, 3, 234
- 95, , , , , Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c, The American Journal of Gastroenterology, 2000, 95, 6, 1524
- 96, , , , Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus, Clinical Infectious Diseases, 2000, 30, s1, S77
- 97, , Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C, Journal of Gastroenterology and Hepatology, 2000, 15,Direct Link:
- 98
- 99, , , , , , Performance Characteristics of a Quantitative, Homogeneous TaqMan RT-PCR Test for HCV RNA, The Journal of Molecular Diagnostics, 2000, 2, 3, 158
- 100, , , , , , , , , A Pilot Study of Daily Subcutaneous Interleukin-10 in Patients with Chronic Hepatitis C Infection, Journal of Interferon & Cytokine Research, 1999, 19, 11, 1265
- 101, , , , Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C, Hepatology, 1999, 30, 5Direct Link:
- 102, , Evolving therapies for the treatment of viral hepatitis, Expert Opinion on Emerging Drugs, 1999, 4, 1, 15
- 103, , , , , , , , Racial differences in responses to therapy with interferon in chronic hepatitis C, Hepatology, 1999, 30, 3Direct Link:
- 104
- 105, , , Ribavirin with or without alpha interferon for chronic hepatitis C, The Cochrane Library,Direct Link: